Black Friday Sale! 50% Off All Access

'Pharma Bro' Martin Shkreli Steps Down as CEO of Turing Pharmaceuticals The poster boy for prescription drug price increases was arrested on securities fraud charges this week.

By Reuters

Entrepreneur+ Black Friday Sale

Our biggest sale — Get unlimited access to Entrepreneur.com at an unbeatable price. Use code SAVE50 at checkout.*

Claim Offer

*Offer only available to new subscribers

This story originally appeared on Reuters

Martin Shkreli | Twitter

Martin Shkreli, the poster boy for prescription drug price increases who was arrested on securities fraud charges this week, has stepped down from his post as chief executive officer of Turing Pharmaceuticals Inc, the company said on Friday.

Shkreli was replaced by Turing Chairman Ron Tilles, who said in a statement that the company was committed to continuing to make its flagship drug, Daraprim, which is used to treat an infection called toxoplasmosis in AIDS patients.

Shkreli has become a lightning rod for growing outrage over soaring prescription drug prices after the company acquired Daraprim and raised its price to $750 a tablet from $13.50.

Turing is the only manufacturer of Daraprim.

Shkreli has been under investigation for securities fraud related to hedge fund MSMB Capital Management and biopharmaceutical company Retrophin Inc (RTRX.O). He was charged in Brooklyn, NY, on Thursday in a federal indictment.

In October 2014, Shkreli was ousted from Retrophin, which he had founded. The drugmaker sued him for $65 million, saying he had breached his duty to the company.

In recent months, Shkreli has made controversial remarks in the press about raising drug prices and taunted detractors, including Democratic presidential candidate Bernie Sanders, on social-media outlets.

Shkreli is also CEO of drugmaker KaloBios Pharmaceuticals Inc. (KBIO.O). KaloBios, which had planned to shut down operations, named him to that post on Nov. 20 after he and a consortium of investors bought about 70 percent of its outstanding shares.

Nasdaq has placed KaloBios' stock on a trading halt until the company provides more information.

On Thursday night, Shkreli, who was released on a $5 million bond earlier in the day, tweeted "Glad to be home. Thanks for the support."

(Reporting by Caroline Humer in New York and Vidya L Nathan in Bengaluru; Editing by Sriraj Kalluvila and Lisa Von Ahn)

Want to be an Entrepreneur Leadership Network contributor? Apply now to join.

Business News

DOGE Leaders Elon Musk and Vivek Ramaswamy Say Mandating In-Person Work Would Make 'a Wave' of Federal Employees Quit

The two published an op-ed outlining their goals for their new department, including workforce reductions.

Real Estate

Why Real Estate Professionals Should Prioritize Social Responsibility

Integrating social responsibility into real estate can foster community change, build trust and drive long-term business success.

Business News

Here's How Much Money You Need to Make in Order to Be 'Successful,' According to Each Generation

A new survey by Empower outlines how Americans of different ages define success.

Business News

The Two Richest People in the World Are Fighting on Social Media Again

Jeff Bezos and Elon Musk had a new, contentious exchange on X.

Starting a Business

Why Are So Many Course Creators Struggling if It's 'Such an Easy Business'? Here's the Truth Behind the $800 Billion Industry

Creating an online course is so easy — at least, that's what many "gurus" would like you to believe. There's a lot of potential in the $800 billion industry, but here's why so many course creators are struggling.

Franchise

McDonald's $5 Meal Deal Will Stay — And a New 'McValue Menu' Is on the Way in 2025

The McValue Menu is slated for a January 2025 debut and will feature a selection of budget-friendly items, allowing customers to customize meals at a lower cost.